Dofetilide: A review of its use in atrial fibrillation and atrial flutter

Drugs

Volumn 58, Issue 6, 1999, Pages 1043-1059

  McClellan, Karen J ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Arrhythmias; Dofetilide; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

ANTIARRHYTHMIC AGENT; DOFETILIDE; SOTALOL;

CARDIOVERSION; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART MUSCLE POTENTIAL; HUMAN; LONG TERM CARE; META ANALYSIS; MORTALITY; POTASSIUM CURRENT; REVIEW; RISK; SINUS RHYTHM; SUDDEN DEATH; TORSADE DES POINTES;

EID: 0033380044     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958060-00007     Document Type: Review

References (89)

1. 1. English KM, Channer KS. Managing atrial fibrillation in elderly people. BMJ 1999 Apr 24; 318: 1088-9
2. 2. Feinberg WM, Blackshear JL., Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995 Mar 13; 155: 469-73
3. 3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8
4. 4. Giardina E-GA. Atrial fibrillation and stroke: elucidating a newly discovered risk factor. Am J Cardiol 1997 Aug 28; 80: 11D-8D
5. 5. DIAMOND Study Group. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patienl characteristics of the DIAMOND studies. Clin Cardiol 1997 Aug; 20: 704-10
6. 6. Narayan SM, Cain ME, Smith JM. Atrial fibrillation. Lancet 1997 Sep 27; 350: 943-50
7. 7. Gilligan DM, Ellenbogen KA, Epstein AE. The management of atrial fibrillation. Am J Med 1996 Oct; 101: 413-21
8. 8. Lévy S, Breithardt G, Camphell RWF, et al. Atrial fibrillation: current knowledge and recommendations for management. Eur Heart J 1998 Sep; 19: 1294-320
9. 9. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation: an evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994 Sep: 48: 345-71
10. 10. Geraets DR, Kienzle MG. Alrial fibrillation and atrial flutter. Clin Pharm 1993; 12: 721-35
11. 11. Grant AO. Mechanisms of atrial fibrillation and action of drugs used in its management. Am J Cardiol 1998 Oct 16; 82 (8A): 43N-9N
12. 12. Sedgwick ML. Lip G, Rae AP, et al. Chemical cardioversion of alrial fibrillation with intravenous dofetilide. Int J Cardiol 1995 Apr; 49: 159-66
13. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 1992 Aug; 262: 809-17
14. +-channel [abstract]. Pharmacologist 1992; 34(3): 165
15. Kr, and effects on myocardial refractoriness for class III antiarrhythmic agents. J Cardiovasc Pharmacol 1995 Feb; 25: 336-40
16. 16. Kiehn J, Villena P, Beyer T, et al. Differential effects of the new class III agent dofetilide on potassium currents in guinea pig cardiomyocytes. J Cardiovasc Pharmacol 1994 Oct; 24: 566-72
17. λk blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990 Sep; 16: 401-10
18. + current by dofetilide. Circ Res 1993 Jan; 72: 75-83
19. 19. Gwilt M, Arrowsmith JE, Blackburn KJ, et al. UK-68798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 1991 Jan; 256: 318-24
20. 20. Knilans TK, Lathrop DA, Nánási PP, et al. Rate and concentration-dependent effects of UK-68,798, a potent new class III antiarrhythmic, on canine Purkinje fibre action potential duration and V max. Br J Pharmacol 1991 Jun; 103: 1568-72
21. 21. Buchanan LV, Kabell G, Brunden MN, et al. Comparative assessment of ibutilide, D-sotalol, elofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993 Oct; 220: 540-9
22. 22. Lindeboom J-E, Kingma JH, Crijns HJGM, et al. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter: a double-blind placebo-controlled study [abstract]. Eur Heart J 1998 Aug; 19 Abstr. Suppl.: 670
23. 23. Crijns HJGM, Van Gelder IC, Kingma JH, et al. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug. Eur Heart J 1994 Oct; 15: 1403-8
24. 24. Suttorp MJ, Polak PE, van't Hof A, et al. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol 1992 Feb 1; 69: 417-9
25. 25. Falk RH, Pollak A, Singh SN, et al. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 1997 Feb; 29: 385-90
26. 26. Sedgwick M, Rasmussen HS, Walker D, et al. Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug. Br J Clin Pharmacol 1991 May; 31: 515-9
27. 27. Beyer ME, Hoffmeister HM, Kazmaier S, et al. Haemodynamic and inotropic effects of the new class-Ill antiarrhythmic drug dofetilide: a comparison with other class-III drugs [abstract]. Eur Heart J 1996 Aug; 17 Abstr. Suppl.: 388
28. 28. Mortensen E, Yang T, Refsum H. Class III antiarrhythmic action and inotropy: effects of dofetilide in acute ischemic heart failure in dogs. J Cardiovasc Pharmacol 1992 Feb; 19: 216-21
29. 29. Rousseau MF, Massart PE, De Kock M, et al. Cardiac function and QT dispersion during IV antiarrhythmic dosing in heart failure patients: superiority of dofetilide over amiodarone [abstract]. Circulation 1996 Oct 15; 94 Suppl.: 1-245
30. 30. DeCara JM, Pollak A, Dubrey S, et al. Positive atrial inotropic effetcs of dofetilide following cardioversion of atrial fibrillation [abstract], J Am Coll Cardiol 1998 Feb; 31 Suppl. 2A: 432A-3A
31. 3H]dofetilide binding to guinea pig myocytes. Circ Res 1995 Oct; 77: 718-25
32. 32. Yang T, Tande PM, Refsum H. Electromechanical action of dofetilide and D-sotalol during simulated metabolic acidosis in isolated guinea pig ventricular muscle. J Cardiovasc Pharmacol 1992 Dec; 20: 889-94
33. 33. Yang T, Tande PM, Lathrop DA, et al. Class III antiarrhythmic action by potassium channel blockade: dofetilide attenuates hypoxia induced electromechanical changes. Cardiovasc Res 1992 Nov; 26: 1109-15
34. 34. Roden DM. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization. Eur Heart J 1993; 14 Suppl. H: 56-61
35. 35. Stratmann HG, Kennedy HL. Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J 1987; 113: 1470-82
36. 36. Black SC, Lucchesi BR. UK-68, 798, a class III antiarrhythmic drug with antifibrillatory properties. Cardiovasc Drug Rev 1992; 10 (2): 170-81
37. 37. Tham TCK, MacLennan BA, Burke MT, et al. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans. J Cardiovasc Pharmacol 1993 Mar; 21: 507-12
38. 38. Le Coz F, Funck-Brentano C, Morell T, et al. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin Pharmacol Ther 1995 May; 57: 533-42
39. 39. Sedgwick ML, Dalrymple I, Rae AP, et al. Effects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris. Eur Heart J 1995 Nov; 16: 1641-6
40. 40. D́molis J-L, Funck-Brentano C, Ropers J, et al. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996 Oct 1; 94: 1592-9
41. 41. Yuan S, Wohlfart B, Rasmussen HS. Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia: A study using simultaneous monophasic action potential recordings from two sites in the right ventricle. Eur Heart J 1994 Apr; 15: 514-22
42. 42. Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol 1992 Dec 1; 70: 1432-7
43. 43. Gjini V, Schreieck J, Korth M, et al. Frequency dependence in the action of the class III antiarrhythmic drug dofetilide is modulated by altering L-type calcium current and digitalis glucoside. J Cardiovasc Pharmacol 1998 Jan; 31: 95-100
44. 44. Funck-Brentano A. Rate-dependence of class III actions in the heart. Fundam Clin Pharmacol 1993; 7: 51-9
45. + current in rabbit ventricular myocytes. Cardiovasc Drugs Ther 1993 Aug; 7 Suppl. 3: 599-604
46. 46. Ohler A, Amos GJ, Wettwer E, et al. Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: no evidence for "reverse use dependent" block. Naunyn Schmiedebergs Arch Pharmacol 1994 Jun: 349: 602-10
47. 47. Gemmill JD, Howie CA, Meredith PA, et al. A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers. Br J Clin Pharmacol 1991 Oct; 32: 429-32
48. 48. Gill J, Heel RC, Fitton A. Amiodarone: an overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992; 43 (1): 69-110
49. 49. Fitton A, Sorkin EM. Sotalol: an updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. Drugs 1993; 46 (4): 678-719
50. 50. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999; 341 (12): 857-65
51. 51. Nichols DJ, McEwen J, Frame MW, et al. Relationship between plasma concentrations and prolongation of QTc for dofetilide, a new class III anti-arrhythmic agent [abstract], 2nd International Symposium Measurement and Kinetics of In Vivo Drug Effects; 1994 Apr 14-16; Noordwijkerhout, The Netherlands: 65-6
52. 52. Gardner MJ, DeMattos SB, Schumacher DA, et al. The effect of food on the PK and PD of dofetilide in healthy male and female subjects [abstract]. J Clin Pharmacol 1997 Sep; 37: 874
53. 53. Smith DA, Rasmussen HS, Stopher DA, et al. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 1992 Jun; 22: 709-19
54. 54. Walker DK, Alabaster CT, Congrave GS, et al. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide: in vitro studies and correlation with in vivo data. Drug Metab Dispos 1996 Apr: 24: 447-55
55. 55. Jones BC, Hyland R, Smith DA, et al. Interaction of dofetilide with cytochrome P450 enzymes [abstract]. Br J Clin Pharmacol 1994 Aug; 38: 170P
56. 56. Noveck R, Vincent J, Gardner M, et al. The safety, toleration, pharmacokinetics and pharmacodynamics of dofetilide in patients with hepatic impairment [abstract]. J Clin Pharmacol 1998 Sep: 38: 884
57. 57. Nichols DJ, Abel S, Eve MD. The effect of cimetidine (100mg bid and 400mg bid) and ranitidine (150mg bid) on the pharmacokinetics and pharmacodynamics of a single dose of dofetilide [abstract]. J Clin Pharmacol 1997 Sep; 37: 877
58. 58. Rasmussen HS, Kleinetmans D, Walker D, et al. A double-blind, placebo controlled parallel group study of the effect of UK-68,798, a novel class III antiarrhythmic agent, on the pharmacokinetics and pharmacodynamics of digoxin [abstract]. Eur Heart J 1990 Aug; II Suppl.: 57
59. 59. Nichols DJ, Dalrymple I, Newgreen MW, et al. The effect of dofetilide on pharmacodynamics of warfarin and pharmacokinetics of digoxin [abstract]. Eur Heart J 1999 Aug-Sep; 20 Abstr. Suppl.: 586
60. 60. Vincent J, Gardner M, Scavone J, et al. The effect of dofetilide on the steady-state PK and cardiac effects of phenytoin in healthy subjects [abstract]. 98th ASCPT 1997 Mar 5: 233
61. 61. Gardner MJ, Ashton HM, Willavize SA, et al. The effects of phenytoin on the steady-state PK and PD of dofetilide in healthy subjects (abstract). 98th ASCPT 1997 Mar 5: 205
62. 62. Vincent J, Gardner MJ, Sherwood J, et al. Glibenclamide does not accentuate QTc changes by dofetilide in healthy subjects [abstract]. 6th ISCP 1996 Feb 26: A29
63. 63. Gardner MJ, Ashton HM, Willavize SA. The effects of orally administered theophylline on the pharmacokinetics and pharmacodynamics of dofetilide [abstract]. Clin Pharmacol Ther 1996 Feb; 59: 182
64. 64. Gardner MJ, Ashton HM, Willavize SA, et al. The effects of concomitant dofetilide therapy on the pharmacokinetics and pharmacodynamics of theophylline [abstract]. Clin Pharmacol Ther 1996 Feb; 59: 181
65. 65. Vincent J, Gardner MJ, Baris B, et al. Concurrent administration of omeprazole and antacid does not alter the pharmacokinetics and pharmacodynamics of dofetilide in healthy subjects [abstract]. Clin Pharmacol Ther 1996 Feb; 59: 182
66. 66. Greenbaum RA, Campbell TJ, Channer KS, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study [abstract]. Circulation 1998 Oct 27; 98 Suppl.: 1-633
67. 67. Singh SN, Berk MR, Yellen LG, et al. Oral dofetilide for conversion of patients with chronic atrial fibrillation or atrial flutter to normal sinus rhythm: a multicenter study [abstract]. J Am Coll Cardiol 1998 Feb; 31 Suppl. 2A: 369A-70A
68. 68. Pedersen OD, DIAMOND Study Group. Dofetilide in the treatment of atrial fibrillation in patients with impaired left ventricular function [abstract]. Eur Heart J 1998 Aug; 19 Abstr. Suppl.: 363
69. 69. Singh SN, Berk MR, Yellen LG, et al. Efficacy and safety of oral dofetilide in maintaining normal sinus in patients with atrial fibrillation/flutter: a multicenter study [abstract]. Circulation 1997 Oct 21; 96 Suppl.: 1-383
70. 70. Lehman R, Grecnbaum RA, Campbell TJ, et al. After one year treatment on dofetilide patients with longer post-cardioversion QT (QTc) interval are more likely to remain in sinus rhythm [abstract]. Eur Heart J 1999 Aug-Sep; 20 Abstr. Suppl.: 586
71. 71. Nørgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Am Heart J 1999 June; 137: 1062-9
72. 72. Bianconi E, Dinelli M, Pappalardo A, et al. Comparison of intravenously-administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicenter, randomized, double-blind, placebo-controlled study [abstract]. Circulation 1995 Oct 15; 92 Suppl. 1: 774
73. 73. Green MS, Dorian P, Roy D, et al. A randomized, double-blind, placebo-controlled comparison of intravenous dofetilide and procainamide in the acute conversion of atrial fibrillation/flutter [abstract]. Can J Cardiol 1997 Sep; 13 Suppl. C: 86C-7C
74. 74. Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. Am J Cardiol 1992; 70: 56A-61A
75. 75. Foster RH, Wilde MI, Markham A. Ibutilide: a review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs 1997 Aug; 54: 312-30
76. 76. Kober L, DIAMOND Study Group. A clinical trial of dofetilide in patients with acute myocardial infarction and left ventricular dysfunction. The DIAMOND MI Study [abstract]. Circulation 1998 Oct 27; 98 Suppl.: 1-93
77. 77. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991 Mar 21; 324: 781-8
78. 78. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996 Jul 6; 348: 7-12
79. 79. Pritchett ELC, Wilkinson WE. Effect of dofetilide on survival in patients with supraventricular arrhythmias. Am Heart J 1999; 138:994-7
80. 80. Roden DM. Current status of class III antiarrhythmic drug therapy. Am J Cardiol 1993 Aug 26; 72: 44B-9B
81. 81. Frost L, Mortensen PE, Tingleff J, et al. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Int J Cardiol 1997 Jan 31 ; 58: 135-40
82. 82. Norgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in the acute termination of atrial fibrillation and flutter. A multicenter, randomized, double-blind, and placebo-controlled trial [abstract]. J Am Coll Cardiol 1997 Feb; 29 Suppl. A: 442A
83. 83. Pfizer Tikosyn dosing requirements could follow Clozaril model - FDA. FDC Pink Sheet 1999 Feb 1; 61: 3-5
84. 84. Planning and Steering Committees of the AFFIRM Study for the NHBL AFFIRM Investigators. Atrial fibrillation follow-up investigation of rhythm management = the AFFIRM Study design. Am J Cardiol 1997; 79: 1198-202
85. 85. Lundström T, Rydén L. Chronic atrial fibrillation. Long-term results of direct current cardioversion. Act Med Scand 1988; 223: 53-9
86. 86. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82: 1106-16
87. 87. Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol 1994 Jan; 9: 12-22
88. 88. Bril A, Faivre J-F, Forest M-C, et al. Electrophysiological effect of BRL-32872, a novel antiarrhythmic agent with potassium and calcium channel blocking properties, in guinea pig cardiac isolated preparations. J Pharmacol Exp Ther 1995 Jun; 273: 1264-72
89. 89. Cavusoglu E, Frishman WH. Sotalol: a new β-adrenergic blocker for ventricular arrhythmias. Prog Cardiovasc Dis 1995 May-Jun; 37: 423-40